Gilead told to waive remdesivir patent rights

Almost 150 health and poverty activist campaigns, including Médecins Sans Frontières, have urged Gilead Sciences to waive patent and exclusivity rights for potential COVID-19 treatment remdesivir.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

US govt doesn’t have remdesivir patent rights, says GAO

1 April 2021 The US government doesn't co-own patents covering Gilead Science’s drug remdesivir, according to a report by the Government Accountability Office.

Big Pharma

Roche secures rights to potential COVID-19 drug

22 October 2020 Swiss pharmaceutical company Roche will pay $350 million for the rights to develop and distribute an investigational COVID-19 antiviral outside of the US.

Generics

Gilead agrees 127-country remdesivir licence with generic makers

14 May 2020 Gilead has agreed to license its antiviral remdesivir to five generic makers for distribution during the COVID-19 pandemic.